Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

2.46 EUR

-1.20 %

2,124 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-1.20 %
-1.20 %
-2.38 %
-12.46 %
-24.77 %
-29.91 %
-23.84 %
-
-51.38 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
82.67M EUR
Turnover
218.68K EUR
P/E (adj.) (25e)
-6.37
EV/EBIT (adj.) (25e)
-7.21
P/B (25e)
6.29
EV/S (25e)
23.68
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
3.20 EUR
Updated
19.11.2025
Disclaimer
Frans-Mikael Rostedt
Antti Luiro
Antti Luiro, Frans-Mikael Rostedt
Show more
Latest research

Latest analysis report

Released: 19.11.2025

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.3
2026

Annual report '25

2.4
2026

General meeting '26

28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Two-year contract for Aiforia in the United States. Inderes Aiforialle sopimus arvostetun yhdysvaltalaisen syöpäinstituutin kanssa - Inderes Aiforialle sopimus arvostetun yhdysvaltalaisen syöpäinstituutin kanssa Aiforia Technologies Oyj, Lehdistötiedote, 30.12.2025 klo 12.00 EETAiforia...
12/30/2025, 10:06 AM
by enska
57
Aiforia’s new shareholder list. Kyösti Kakkonen (Joensuun Kauppa Ja Kone Oy) as a new owner directly at 30th place. Aiforia Aiforia - Osakkeenomistajat Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa ...
1/2/2026, 12:38 PM
by TO
35
Inderes’ extensive report: “In the United States, the customer can also self-validate an AI model they have developed for clinical use (referred to in the US by the term LDT, Lab Developed Test). In these cases, Aiforia sells its software for research purposes and the customer handles...
12/30/2025, 2:26 PM
by Vino Pino
24
It might be worth noting that, at least in light of Aiforia’s press release, the latest US order is for scientific research use, rather than routine clinical use with large patient datasets. A good reference for sure, but it might not have extraordinary significance for Aiforia’s...
12/30/2025, 1:03 PM
by veronmaksaja
14
Well spotted… Maybe @Antti_Luiro could ask about this in the next interview? It could be that there is a sensible explanation for this, but I’ve started to feel that CEO Tapaninen’s talk contains even more hype than usual. All tenders are won, demand is strong, and great new partnerships...
12/23/2025, 9:59 PM
14
On the other hand, he just put in over half a mil of his own cash, so that’s certainly enough heat for one Christmas sauna! The only thing I’m wondering about is the cost structure—could it be trimmed, or what does it even consist of? Personnel costs are over €100k/annum/head; I ...
12/24/2025, 7:13 AM
by Puutaheinää
12
Order to the US for Aiforia Will the share price reach new heights? Remains as the year’s final news New CFO looks toward the West?
12/30/2025, 12:01 PM
by slipslop
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.